Antitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivo

Yang,Guohua; Meng,Xiangwei; Sun,Lili; Hu,Ningning; Jiang,Shuang; Sheng,Yuan; Chen,Zhifei; Zhou,Ye; Chen,Dexing; Li,Xiao; Jin,Ningyi

doi:10.3892/etm.2014.2086

Antitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivo

Authors:
- Guohua Yang
- Xiangwei Meng
- Lili Sun
- Ningning Hu
- Shuang Jiang
- Yuan Sheng
- Zhifei Chen
- Ye Zhou
- Dexing Chen
- Xiao Li
- Ningyi Jin
View Affiliations

Affiliations: Department of Gastroenterology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Head and Neck Surgery, Jilin Province Tumor Hospital, Changchun, Jilin 130001, P.R. China, Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, Jilin 130122, P.R. China, Jilin Province Qianwei Hospital, Changchun, Jilin 130031, P.R. China
Published online on: November 24, 2014 https://doi.org/10.3892/etm.2014.2086
Pages: 327-334
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy and specificity of treatment are major challenges for cancer gene therapy. Oncolytic virotherapy is an attractive drug delivery platform for cancer gene therapy. In the present study, the dual‑specific antitumor oncolytic adenovirus, Ad‑Apoptin‑hTERT‑E1a, was used to infect SW1116 human colorectal carcinoma (CRC) cell lines and CT26 mouse‑CRC‑cell bearing BALB/c mouse models for testing antitumor effects in vitro and in vivo. The in vitro assays revealed that infection with Ad‑Apoptin‑hTERT‑E1a induced a significant cytotoxic effect on the CRC cell line, SW1116; however, the normal human cell line, GES, was only slightly inhibited by the recombinant adenovirus. Acridine orange and ethidium bromide staining and an annexin V assay indicated that infection of SW1116 cells with Ad‑Apoptin‑hTERT‑E1a resulted in a significant induction of apoptosis. Furthermore, western blotting and flow cytometry revealed a decrease in the mitochondrial membrane potential (MMP), the release of cytochrome c and the activation of caspase 3, 6 and 7 in Ad‑Apoptin‑hTERT‑E1a‑infected SW1116 cells. In the animal models, Ad‑Apoptin‑hTERT‑E1a was shown to significantly inhibit tumor growth and extend the survival times of the animals. Therefore, the experimental results indicated that Ad‑Apoptin‑hTERT‑E1a has potential for application in tumor gene therapy.

View Figures

View References

1	Li ST and Chi P: Evolution of the management of colorectal cancer using integrative medicine. Chin J Integr Med. 17:73–79. 2011. View Article : Google Scholar : PubMed/NCBI
2	Waldner MJ and Neurath MF: The molecular therapy of colorectal cancer. Mol Aspects Med. 31:171–178. 2010. View Article : Google Scholar : PubMed/NCBI
3	Barnes MN and Pustilnik TB: Current strategies in gene therapy for ovarian cancer. Curr Opin Obstet Gynecol. 13:47–51. 2001. View Article : Google Scholar : PubMed/NCBI
4	Shirakawa T: The current status of adenovirus-based cancer gene therapy. Mol Cells. 25:462–466. 2008.PubMed/NCBI
5	Kang E and Yun CO: Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity. BMB Rep. 43:781–788. 2010. View Article : Google Scholar : PubMed/NCBI
6	Pesonen S, Kangasniemi L and Hemminki A: Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm. 8:12–28. 2011. View Article : Google Scholar
7	Panigrahi S, Klonisch T and Los M: The art of killing: double stroke with apoptin and survivin as a novel approach in cancer therapy. Cancer Biol Ther. 7:1061–1062. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hashimoto Y, Tazawa H, Teraishi F, et al: The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment. PLoS One. 7:e392922012. View Article : Google Scholar : PubMed/NCBI
9	Kovalenko OA, Kaplunov J, Herbig U, et al: Expression of (NES-)hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stress. PLoS One. 5:e108122010. View Article : Google Scholar : PubMed/NCBI
10	Chan G, Kamarudin MN, Wong DZ, et al: Mitigation of H(2)O(2)-induced mitochondrial-mediated apoptosis in NG108-15 cells by novel mesuagenin C from Mesua kunstleri (King) Kosterm. Evid Based Complement Alternat Med. 2012:1565212012. View Article : Google Scholar : PubMed/NCBI
11	Byczkowska A, Kunikowska A and Kaźmierczak A: Determination of ACC-induced cell-programmed death in roots of Vicia faba ssp minor seedlings by acridine orange and ethidium bromide staining. Protoplasma. 250:121–128. 2013. View Article : Google Scholar :
12	Li X1, Liu Y, Wen Z, et al: Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer. 9:102010. View Article : Google Scholar : PubMed/NCBI
13	Zhang M, Wang J, Li C, et al: Potent growth-inhibitory effect of a dual cancer-specific oncolytic adenovirus expressing apoptin on prostate carcinoma. Int J Oncol. 42:1052–1060. 2013.PubMed/NCBI
14	Los M, Panigrahi S, Rashedi I, et al: Apoptin, a tumor-selective killer. Biochim Biophys Acta. 1793:1335–1342. 2009. View Article : Google Scholar : PubMed/NCBI
15	Backendorf C, Visser AE, de Boer AG, et al: Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol. 48:143–169. 2008. View Article : Google Scholar
16	Pavet V, Portal MM, Moulin JC, Herbrecht R and Gronemeyer H: Towards novel paradigms for cancer therapy. Oncogene. 30:1–20. 2011. View Article : Google Scholar
17	Ye F, Zhong B, Dan G, et al: Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct. Arch Med Sci. 9:561–568. 2013. View Article : Google Scholar : PubMed/NCBI
18	O’Sullivan RJ and Karlseder J: Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol. 11:171–181. 2010.
19	Antoniou KM, Margaritopoulos GA, Proklou A, et al: Investigation of telomerase/telomeres system in bone marrow mesenchymal stem cells derived from IPF and RA-UIP. J Inflamm (Lond). 9:272012. View Article : Google Scholar
20	Vähä-Koskela MJ, Heikkilä JE and Hinkkanen AE: Oncolytic viruses in cancer therapy. Cancer Lett. 254:178–216. 2007. View Article : Google Scholar : PubMed/NCBI
21	Nettelbeck DM: Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med (Berl). 86:363–377. 2008. View Article : Google Scholar
22	Wu Y, Zhang X, Wang X, et al: Apoptin enhances the oncolytic properties of Newcastle disease virus. Intervirology. 55:276–286. 2012. View Article : Google Scholar
23	Jiang J, Cole D, Westwood N, et al: Crucial roles for protein kinase C isoforms in tumor-specific killing by apoptin. Cancer Res. 70:7242–7252. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kang X, Chen W, Kim RH, Kang MK and Park NH: Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene. 28:565–574. 2009. View Article : Google Scholar
25	Xie X, Hsu JL, Choi MG, et al: A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 8:2375–2382. 2009. View Article : Google Scholar : PubMed/NCBI
26	Tan J, Li W and Wang P: Telomerase reverse transcriptase promoter-driven expression of iodine pump genes for targeted radioiodine therapy of malignant glioma cells. Chin J Cancer. 30:574–580. 2011. View Article : Google Scholar : PubMed/NCBI
27	Liu L, Wu W, Zhu G, et al: Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma. Int J Mol Med. 30:747–754. 2012.PubMed/NCBI